Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am asking more traders to get 2's next week and clear them out our way
Go $DCAC
Agreed
Go $DCAC
$ERBB chart is heating up
Go $ERBB
$MPEL Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=MPEL
$MPEL Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=MPEL
$POTG Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=POTG
$POTG Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=POTG
$ISBG Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=ISBG
$ISBG Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=ISBG
$ISBG Technical Analysis
http://www.stockta.com/cgi-bin/analysis.pl?symb=ISBG&cobrand=&mode=stock
$ISBG Technical Analysis
http://www.stockta.com/cgi-bin/analysis.pl?symb=ISBG&cobrand=&mode=stock
Yes it is Tesla Model X. $140K out the door Buddy
Thanks My Friend
$PMCB What Are Clinical Stage Biotech Stocks?
Many small cap biotech stocks like Pharmacyte Biotech Inc (OTCQB: PMCB) call themselves “clinical stage biotech stock.” Here is what you need to know when a biotech stock says they are in the clinical stage.
If you are an investor new to biotech investing, you might be wondering what is meant when a small cap biotech stock like Pharmacyte Biotech Inc (OTCQB: PMCB) calls themselves a “clinical stage biotech stock” or company. After all, many small cap biotech stocks like Pharmacyte Biotech are still in the clinical stage; but such stocks tend to not be the best of investments for risk adverse or novice investors.
What Are Clinical Stage Biotech Stocks?
When a small cap biotech stock calls themselves a clinical stage biotech stock, it usually means they do not yet have any drugs or treatments approved by the FDA or other appropriate regulatory authorities in other countries. For that reason, you should be aware of and have an understanding of the phases of drug development:
An Investigational New Drug Application (IND) is made to the FDA showing results of any study done in the laboratory.
Clinical Phase I involves studies performed on a small group of healthy volunteers to see how a new drug is metabolized in the human body as well as to determine the dose and dosage interval that will have a positive effect on the disease or problem without unwanted side-effects.
Clinical Phase II involves treating a larger group of patients to demonstrate a new drug's efficacy and to confirm its safety with comparisons often being made with another group receiving inactive placebo treatment.
Clinical Phase III’s main goal is to prove that any promising effects seen in Phase II can also be obtained in larger patient groups with great importance being attached to safety issues, documentation and production preparations.
Submission of a New Drug Application to the FDA will usually occur at this point and it should be kept in mind there is still no guarantee that the FDA will approve something – even if Phase I to Phase III trials or studies resulted in positive data or results. Sometime the FDA will ask for further studies or clarifications.
Keep in mind that most drug clinical trials will fail to achieve their goals – meaning you should look for clinical stage biotech stocks that have diversified drug pipelines or are building drug platforms that have the potential to treat multiple conditions.
With that said and if you are a risk adverse investor, you would be better off buying established biotech stocks that are beyond the clinical stage with approved drugs, are profitable and have developed drug pipelines. The downside about such biotech stocks is that they are already on Wall Street's radar and the trading screen of every other biotech stock trader/investor out there – meaning you have probably missed the big homerun, share pop or lottery ticket winner.
Clinical Stage Biotech Stock Example: PharmaCyte Biotech
Small cap PharmaCyte Biotech is a good example of a clinical stage biotechnology company that’s probably still off the radar screen of Wall Street and most biotech investors as its still trading on the OTC. PharmaCyte Biotech is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
More specifically, the technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are then nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them.
PharmaCyte Biotech’s Cell-in-a-Box encapsulation differs from those produced by others as competitors use substances such as alginate (a seaweed derivative) or chitosan whereas PMCB’s capsules are made principally of cellulose, a bio-inert material in the human body.
For the second half of the year, PharmaCyte Biotech has been busy making various announcements worth noting by investors:
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
Mon, 25 Jan 2016 14:25:00 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[GlobeNewswire] - SILVER SPRING, Md., Jan. 25, 2016-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-executives-meet-translational-drug-142500942.html
*********************************************************
Sat, 23 Jan 2016 18:04:15 GMT ~ PHARMACYTE BIOTECH, INC. Financials
read full: http://finance.yahoo.com/q/is?s=pmcb
*********************************************************
Thu, 21 Jan 2016 14:12:00 GMT ~ The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/road-ahead-featured-research-spectrascience-141200909.html
*********************************************************
Tue, 19 Jan 2016 22:34:55 GMT ~ PHARMACYTE BIOTECH, INC. Files SEC form 10-K/A, Annual Report
read full: http://biz.yahoo.com/e/160119/pmcb10-k_a.html
*********************************************************
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board Marketwired (Tue, Jul 21)
PharmaCyte Biotech would be down 62.8% since the start of the year – not necessarily a bad sign as the stock is a clinical stage biotech. Nevertheless, shares are still up 346.7% over the past five years.
$PMCB What Are Clinical Stage Biotech Stocks?
Many small cap biotech stocks like Pharmacyte Biotech Inc (OTCQB: PMCB) call themselves “clinical stage biotech stock.” Here is what you need to know when a biotech stock says they are in the clinical stage.
If you are an investor new to biotech investing, you might be wondering what is meant when a small cap biotech stock like Pharmacyte Biotech Inc (OTCQB: PMCB) calls themselves a “clinical stage biotech stock” or company. After all, many small cap biotech stocks like Pharmacyte Biotech are still in the clinical stage; but such stocks tend to not be the best of investments for risk adverse or novice investors.
What Are Clinical Stage Biotech Stocks?
When a small cap biotech stock calls themselves a clinical stage biotech stock, it usually means they do not yet have any drugs or treatments approved by the FDA or other appropriate regulatory authorities in other countries. For that reason, you should be aware of and have an understanding of the phases of drug development:
An Investigational New Drug Application (IND) is made to the FDA showing results of any study done in the laboratory.
Clinical Phase I involves studies performed on a small group of healthy volunteers to see how a new drug is metabolized in the human body as well as to determine the dose and dosage interval that will have a positive effect on the disease or problem without unwanted side-effects.
Clinical Phase II involves treating a larger group of patients to demonstrate a new drug's efficacy and to confirm its safety with comparisons often being made with another group receiving inactive placebo treatment.
Clinical Phase III’s main goal is to prove that any promising effects seen in Phase II can also be obtained in larger patient groups with great importance being attached to safety issues, documentation and production preparations.
Submission of a New Drug Application to the FDA will usually occur at this point and it should be kept in mind there is still no guarantee that the FDA will approve something – even if Phase I to Phase III trials or studies resulted in positive data or results. Sometime the FDA will ask for further studies or clarifications.
Keep in mind that most drug clinical trials will fail to achieve their goals – meaning you should look for clinical stage biotech stocks that have diversified drug pipelines or are building drug platforms that have the potential to treat multiple conditions.
With that said and if you are a risk adverse investor, you would be better off buying established biotech stocks that are beyond the clinical stage with approved drugs, are profitable and have developed drug pipelines. The downside about such biotech stocks is that they are already on Wall Street's radar and the trading screen of every other biotech stock trader/investor out there – meaning you have probably missed the big homerun, share pop or lottery ticket winner.
Clinical Stage Biotech Stock Example: PharmaCyte Biotech
Small cap PharmaCyte Biotech is a good example of a clinical stage biotechnology company that’s probably still off the radar screen of Wall Street and most biotech investors as its still trading on the OTC. PharmaCyte Biotech is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
More specifically, the technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are then nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them.
PharmaCyte Biotech’s Cell-in-a-Box encapsulation differs from those produced by others as competitors use substances such as alginate (a seaweed derivative) or chitosan whereas PMCB’s capsules are made principally of cellulose, a bio-inert material in the human body.
For the second half of the year, PharmaCyte Biotech has been busy making various announcements worth noting by investors:
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
Mon, 25 Jan 2016 14:25:00 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[GlobeNewswire] - SILVER SPRING, Md., Jan. 25, 2016-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-executives-meet-translational-drug-142500942.html
*********************************************************
Sat, 23 Jan 2016 18:04:15 GMT ~ PHARMACYTE BIOTECH, INC. Financials
read full: http://finance.yahoo.com/q/is?s=pmcb
*********************************************************
Thu, 21 Jan 2016 14:12:00 GMT ~ The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/road-ahead-featured-research-spectrascience-141200909.html
*********************************************************
Tue, 19 Jan 2016 22:34:55 GMT ~ PHARMACYTE BIOTECH, INC. Files SEC form 10-K/A, Annual Report
read full: http://biz.yahoo.com/e/160119/pmcb10-k_a.html
*********************************************************
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board Marketwired (Tue, Jul 21)
PharmaCyte Biotech would be down 62.8% since the start of the year – not necessarily a bad sign as the stock is a clinical stage biotech. Nevertheless, shares are still up 346.7% over the past five years.
$PMCB Pharmacyte Biotech is Poised to Rock the Diabetes Treatment Boat
After a century of maintaining the status quo, Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is working on a quantum leap in the treatment of diabetes.
While the last few decades have seen some amazing advances in medicine, one area that hasn't changed much - if at all - is diabetes treatments. The current standard of care is insulin injections, and though they've certainly improved since first being introduced back in the 1920's the basic premise is no different now than it was then. A small, up-and-coming biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), may be about to change the diabetes treatment paradigm.
Diabetes, in simplest terms, is an excess of glucose (sugar) in the bloodstream. Normally the human body can process and remove this glucose with insulin produced naturally produced by the pancreas. For diabetics, however, the insulin-producing beta cells in the pancreas are destroyed by that body's immune system. Though type 2 diabetes can often be treated by weight loss and better dietary habits, type 1 diabetes - "the bad one" - cannot be self-regulated by diet and exercise.
Proposed solutions to the type 1 diabetes problem have been varied, and each has its merits.
The simplest solution (and the one still primarily used) was, as noted, is injecting insulin into the diabetic patient's bloodstream. This is the solution Novo Nordisk A/S (NYSE:NVO) introduced nearly a century ago. The downside? Even a small needle is still a needle, and the required dosage is forever changing with a diabetic's glucose levels.
MannKind Corporation (NASDAQ:MNKD) arguably introduced the biggest leap in the world of insulin treatments last year, winning the FDA's approval for AFREZZA... and inhaled form of insulin. While this approach circumvents the needle, questions remain over the long-term safety of delivering insulin through the lungs.
And in between those two milestones, several companies toyed with the idea of depositing or replacing the islet cells in the pancreas as a therapy for type 1 diabetes, which would effectively serve as a cure for the disease. These ideas showed promise too, but were largely problematic. Either these cells were still ultimately attacked by the immune system, or the mechanical structure required to place them in the pancreas failed.
To this day, the only viable treatment of type 1 diabetes is the original one... forcing insulin into the bloodstream from outside the body, one way or another. Pharmacyte Biotech may be about to change this with what could effectively be seen as a cure for the disease.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed within the pancreas. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
It's an idea that's been tried before, but as was noted, it's an idea that's generally failed one way or another. The game-changer Pharmacyte brings to the table, however, is the Cell-in-a-Box encapsulation biotechnology.
The key to Cell-in-a-Box is the combination of the right polymers added to the mix in the right way at the right time.
The process starts out with a mix of live cells (insulin-producing pancreatic cells in this case) and a polymer which is then passed through a droplet-forming device into a bath of another proprietary polymer. When the two polymers meet, a membrane is formed, with the living cells inside of it. This membrane keeps the cells in, lets insulin out, lets nutrients in, and most important, prevents the body's immune system from destroying these cells.... something most previous encapsulation attempts couldn't do.
And that's the proverbial quantum leap for diabetics - an encapsulation technology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical research phase, though it was recently validated as a safe biotechnology by University of Veterinary Medicine Vienna. Then again, its confirmed safety can't even be counted as a pleasant surprise, as it's the same delivery technology that's now part of a phase 2 study as a treatment means for pancreatic cancer.
Whatever the case, Pharmacyte Biotech is one step closer to beginning human clinical trials of the diabetes treatment approach. That alone could prove catalytic for its stock, as it has the potential to change the way the world thinks about treating diabetes.
$PMCB Pharmacyte Biotech is Poised to Rock the Diabetes Treatment Boat
After a century of maintaining the status quo, Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is working on a quantum leap in the treatment of diabetes.
While the last few decades have seen some amazing advances in medicine, one area that hasn't changed much - if at all - is diabetes treatments. The current standard of care is insulin injections, and though they've certainly improved since first being introduced back in the 1920's the basic premise is no different now than it was then. A small, up-and-coming biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), may be about to change the diabetes treatment paradigm.
Diabetes, in simplest terms, is an excess of glucose (sugar) in the bloodstream. Normally the human body can process and remove this glucose with insulin produced naturally produced by the pancreas. For diabetics, however, the insulin-producing beta cells in the pancreas are destroyed by that body's immune system. Though type 2 diabetes can often be treated by weight loss and better dietary habits, type 1 diabetes - "the bad one" - cannot be self-regulated by diet and exercise.
Proposed solutions to the type 1 diabetes problem have been varied, and each has its merits.
The simplest solution (and the one still primarily used) was, as noted, is injecting insulin into the diabetic patient's bloodstream. This is the solution Novo Nordisk A/S (NYSE:NVO) introduced nearly a century ago. The downside? Even a small needle is still a needle, and the required dosage is forever changing with a diabetic's glucose levels.
MannKind Corporation (NASDAQ:MNKD) arguably introduced the biggest leap in the world of insulin treatments last year, winning the FDA's approval for AFREZZA... and inhaled form of insulin. While this approach circumvents the needle, questions remain over the long-term safety of delivering insulin through the lungs.
And in between those two milestones, several companies toyed with the idea of depositing or replacing the islet cells in the pancreas as a therapy for type 1 diabetes, which would effectively serve as a cure for the disease. These ideas showed promise too, but were largely problematic. Either these cells were still ultimately attacked by the immune system, or the mechanical structure required to place them in the pancreas failed.
To this day, the only viable treatment of type 1 diabetes is the original one... forcing insulin into the bloodstream from outside the body, one way or another. Pharmacyte Biotech may be about to change this with what could effectively be seen as a cure for the disease.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed within the pancreas. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
It's an idea that's been tried before, but as was noted, it's an idea that's generally failed one way or another. The game-changer Pharmacyte brings to the table, however, is the Cell-in-a-Box encapsulation biotechnology.
The key to Cell-in-a-Box is the combination of the right polymers added to the mix in the right way at the right time.
The process starts out with a mix of live cells (insulin-producing pancreatic cells in this case) and a polymer which is then passed through a droplet-forming device into a bath of another proprietary polymer. When the two polymers meet, a membrane is formed, with the living cells inside of it. This membrane keeps the cells in, lets insulin out, lets nutrients in, and most important, prevents the body's immune system from destroying these cells.... something most previous encapsulation attempts couldn't do.
And that's the proverbial quantum leap for diabetics - an encapsulation technology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical research phase, though it was recently validated as a safe biotechnology by University of Veterinary Medicine Vienna. Then again, its confirmed safety can't even be counted as a pleasant surprise, as it's the same delivery technology that's now part of a phase 2 study as a treatment means for pancreatic cancer.
Whatever the case, Pharmacyte Biotech is one step closer to beginning human clinical trials of the diabetes treatment approach. That alone could prove catalytic for its stock, as it has the potential to change the way the world thinks about treating diabetes.
$PMCB Stonegate Capital Partners Publishes Research Report on PharmaCyte Biotech
SILVER SPRING, Md., Feb. 10, 2016 -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Stonegate Capital Partners (Stonegate), a privately held corporate advisory firm based in Dallas, Texas, with offices in New York and Boston, issued a Research Report featuring PharmaCyte Biotech. The report can be viewed at http://stonegateinc.com/reports/Pharma_Feb_2016.pdf
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented on the report saying, “In our opinion the Research Report released by Stonegate Capital Partners and authored by Senior Research Analyst Laura S. Engel is comprehensive and captures the essence of what we are trying to accomplish at PharmaCyte. Particular emphasis is placed on the two major programs underway that employ our proprietary Cell-in-a-Box® live-cell encapsulation technology to tackle two of the most difficult to treat diseases in the world - cancer and diabetes.”
Stonegate’s Senior Research Analyst, Laura S. Engel, authored the Research Report, which focuses on PharmaCyte’s clinical development of a variety of potential therapies across several areas of disease utilizing its novel live cell encapsulation platform, Cell-in-a-Box®.
Stonegate’s Senior Research Analyst writes that PharmaCyte offers a significant opportunity for investors looking to participate in this development. “We believe that PMCB has a solid pathway towards commercialization with the approach outlined for its Phase 2b study for pancreatic cancer patients set to begin in the Q2-Q3 of calendar year 2016. Additionally, management will be actively moving other potential treatments along; these treatments are related to malignant ascites fluid accumulation in the abdomens of patients with abdominal cancers and Type 1 and Type 2 diabetes. Positive news flow should yield investor returns as the Company accomplishes its milestones that have been set for 2016.”
Senior Research Analyst Laura S. Engel started a career in public accounting following graduation from the University of Virginia, McIntire School of Business, with a B.S. in Accounting. After several years with Arthur Andersen, Engel transitioned in industry where she worked for several publicly traded companies, managing both domestic and international accounting operations. Engel subsequently transitioned into the finance realm, joining a Financial Services consulting team with KPMG Consulting focusing on systems implementations for several Wall Street banks. She later joined a smaller wealth management group, servicing a book of clientele through investment management and financial planning. Since 2003, Engel has teamed with Stonegate and worked in several areas of the business.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (prodrug) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: info@PharmaCyte.com
http://www.econotimes.com/Stonegate-Capital-Partners-Publishes-Research-Report-on-PharmaCyte-Biotech-158732
$PMCB Stonegate Capital Partners Publishes Research Report on PharmaCyte Biotech
SILVER SPRING, Md., Feb. 10, 2016 -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Stonegate Capital Partners (Stonegate), a privately held corporate advisory firm based in Dallas, Texas, with offices in New York and Boston, issued a Research Report featuring PharmaCyte Biotech. The report can be viewed at http://stonegateinc.com/reports/Pharma_Feb_2016.pdf
PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented on the report saying, “In our opinion the Research Report released by Stonegate Capital Partners and authored by Senior Research Analyst Laura S. Engel is comprehensive and captures the essence of what we are trying to accomplish at PharmaCyte. Particular emphasis is placed on the two major programs underway that employ our proprietary Cell-in-a-Box® live-cell encapsulation technology to tackle two of the most difficult to treat diseases in the world - cancer and diabetes.”
Stonegate’s Senior Research Analyst, Laura S. Engel, authored the Research Report, which focuses on PharmaCyte’s clinical development of a variety of potential therapies across several areas of disease utilizing its novel live cell encapsulation platform, Cell-in-a-Box®.
Stonegate’s Senior Research Analyst writes that PharmaCyte offers a significant opportunity for investors looking to participate in this development. “We believe that PMCB has a solid pathway towards commercialization with the approach outlined for its Phase 2b study for pancreatic cancer patients set to begin in the Q2-Q3 of calendar year 2016. Additionally, management will be actively moving other potential treatments along; these treatments are related to malignant ascites fluid accumulation in the abdomens of patients with abdominal cancers and Type 1 and Type 2 diabetes. Positive news flow should yield investor returns as the Company accomplishes its milestones that have been set for 2016.”
Senior Research Analyst Laura S. Engel started a career in public accounting following graduation from the University of Virginia, McIntire School of Business, with a B.S. in Accounting. After several years with Arthur Andersen, Engel transitioned in industry where she worked for several publicly traded companies, managing both domestic and international accounting operations. Engel subsequently transitioned into the finance realm, joining a Financial Services consulting team with KPMG Consulting focusing on systems implementations for several Wall Street banks. She later joined a smaller wealth management group, servicing a book of clientele through investment management and financial planning. Since 2003, Engel has teamed with Stonegate and worked in several areas of the business.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (prodrug) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: info@PharmaCyte.com
http://www.econotimes.com/Stonegate-Capital-Partners-Publishes-Research-Report-on-PharmaCyte-Biotech-158732
$PMCB Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, said that his company's recent decision to partner with a privately held San Diego biotech was to "hedge our bets to make sure we would win in this space." Johnson & Johnson's deal with ViaCyte, Inc. is an effort to speed up the development of ViaCyte's stem cell treatment for Type 1 diabetes. Winning in the diabetes space, however, might mean that Johnson & Johnson or another larger company in the biopharmaceutical industry will need to take a long look at PharmaCyte Biotech (OTCQB: PMCB), a small Silver Spring, Maryland firm with its own Type 1 diabetes treatment.
After sitting in on PharmaCyte's second annual International Diabetes Consortium meeting in Vienna, Austria, it was clear that PharmaCyte has a treatment that many other companies, organizations and research institutes have yet to prove they're capable of producing. It is this treatment that Johnson & Johnson and other biopharmaceutical companies should be eyeing very closely. In order to pull off the feat of developing a successful treatment or "cure" for those who are insulin dependent, most researchers are looking for three key ingredients. And PharmaCyte has all three: (1) a cell line capable of producing insulin that can act as an "artificial pancreas," (2) an encapsulation technology that can house the cell line inside the body and keep it protected from the body's immune system, and finally (3) a team of experts in the diabetes arena that can bring the treatment to life.
PharmaCyte's treatment for type 1 diabetes and type 2 insulin-dependent diabetes is an encapsulated human cell line, called the Melligen cell line, which are liver cells that have been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. PharmaCyte will encapsulate the Melligen cells using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Developing a successful diabetes treatment for Type 1 diabetics all starts with a cell line that is capable of producing insulin on demand. Unlike most who have turned to islet cells or stem cells, PharmaCyte has instead turned to Professor Ann Simpson, one of the 17 members on PharmaCyte's international diabetes consortium, and her colleagues at the University of Technology-Sydney in Australia. Professor Simpson and her team conducted numerous tests during the various stages of the development process and studies were carried out to show that Melligen cells secreted insulin in response to physiological concentrations of glucose (blood sugar). Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.
Their work was published in a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development: http://www.nature.com/articles/mtm201511
The authors of the article note that, for the Melligen cells to be effective in treating Type 1 diabetes in humans where the insulin-producing beta cells of the pancreas have been destroyed, it will be necessary to protect these cells from rejection by the body's immune system after they have been introduced into the body. The article points out that one way to protect the Melligen cells would be to encapsulate the cells in protective "cocoons" prior to being placed into a diabetic patient. If this is done, the authors believe that encapsulated Melligen cells may offer a cure for Type 1 diabetes.
Enter step 2 of PharmaCyte Biotech's three-pronged approach, an encapsulation technology capable of protecting the genetically engineered live cells inside. The ability to encapsulate a cell line and keep it protected from immune system attack to treat diabetes has been called the "holy grail" of cell encapsulation. PharmaCyte's live-cell encapsulation technology, Cell-in-a-Box®, appears to be the ideal encapsulation technology for this purpose. In fact, Melligen cells have already been successfully encapsulated using the Cell-in-a-Box® process, and the first preclinical studies have shown that Melligen cells are equally as safe inside the Cell-in-a-Box® capsules as the encapsulated cells that PharmaCyte will be using in its upcoming FDA human clinical trials in advanced pancreatic cancer.
So, with the Melligen cell line in place, and with Cell-in-a-Box® set to house the cell line to keep it protected, the final piece to developing a successful treatment for Type 1 diabetes is a team of experts who can put it all together, test it, modify the treatment where necessary, perfect the dosing in a number of animal models and get the treatment into clinical trials as quickly as possible.
PharmaCyte's CEO, Kenneth L. Waggoner, has assembled 17 experts in the field of diabetes from all over the globe. This group makes up PharmaCyte's International Diabetes Consortium. They have all come together to work toward one goal -- developing an "artificial pancreas" or a "cure" for insulin dependent diabetes. All of these experts are working at the same time in their specific area of expertise rather than waiting for each experiment to run its course before moving on to the next group of experts. It is this approach that should expedite PharmaCyte's path to human clinical trials. PharmaCyte's approach should provide answers more quickly for those larger biopharmaceuticals that expect to win the race to the first truly long-term successful type 1 diabetes treatment.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
For more information: www.stockmarketmediagroup.com.
$PMCB Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, said that his company's recent decision to partner with a privately held San Diego biotech was to "hedge our bets to make sure we would win in this space." Johnson & Johnson's deal with ViaCyte, Inc. is an effort to speed up the development of ViaCyte's stem cell treatment for Type 1 diabetes. Winning in the diabetes space, however, might mean that Johnson & Johnson or another larger company in the biopharmaceutical industry will need to take a long look at PharmaCyte Biotech (OTCQB: PMCB), a small Silver Spring, Maryland firm with its own Type 1 diabetes treatment.
After sitting in on PharmaCyte's second annual International Diabetes Consortium meeting in Vienna, Austria, it was clear that PharmaCyte has a treatment that many other companies, organizations and research institutes have yet to prove they're capable of producing. It is this treatment that Johnson & Johnson and other biopharmaceutical companies should be eyeing very closely. In order to pull off the feat of developing a successful treatment or "cure" for those who are insulin dependent, most researchers are looking for three key ingredients. And PharmaCyte has all three: (1) a cell line capable of producing insulin that can act as an "artificial pancreas," (2) an encapsulation technology that can house the cell line inside the body and keep it protected from the body's immune system, and finally (3) a team of experts in the diabetes arena that can bring the treatment to life.
PharmaCyte's treatment for type 1 diabetes and type 2 insulin-dependent diabetes is an encapsulated human cell line, called the Melligen cell line, which are liver cells that have been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. PharmaCyte will encapsulate the Melligen cells using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Developing a successful diabetes treatment for Type 1 diabetics all starts with a cell line that is capable of producing insulin on demand. Unlike most who have turned to islet cells or stem cells, PharmaCyte has instead turned to Professor Ann Simpson, one of the 17 members on PharmaCyte's international diabetes consortium, and her colleagues at the University of Technology-Sydney in Australia. Professor Simpson and her team conducted numerous tests during the various stages of the development process and studies were carried out to show that Melligen cells secreted insulin in response to physiological concentrations of glucose (blood sugar). Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.
Their work was published in a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development: http://www.nature.com/articles/mtm201511
The authors of the article note that, for the Melligen cells to be effective in treating Type 1 diabetes in humans where the insulin-producing beta cells of the pancreas have been destroyed, it will be necessary to protect these cells from rejection by the body's immune system after they have been introduced into the body. The article points out that one way to protect the Melligen cells would be to encapsulate the cells in protective "cocoons" prior to being placed into a diabetic patient. If this is done, the authors believe that encapsulated Melligen cells may offer a cure for Type 1 diabetes.
Enter step 2 of PharmaCyte Biotech's three-pronged approach, an encapsulation technology capable of protecting the genetically engineered live cells inside. The ability to encapsulate a cell line and keep it protected from immune system attack to treat diabetes has been called the "holy grail" of cell encapsulation. PharmaCyte's live-cell encapsulation technology, Cell-in-a-Box®, appears to be the ideal encapsulation technology for this purpose. In fact, Melligen cells have already been successfully encapsulated using the Cell-in-a-Box® process, and the first preclinical studies have shown that Melligen cells are equally as safe inside the Cell-in-a-Box® capsules as the encapsulated cells that PharmaCyte will be using in its upcoming FDA human clinical trials in advanced pancreatic cancer.
So, with the Melligen cell line in place, and with Cell-in-a-Box® set to house the cell line to keep it protected, the final piece to developing a successful treatment for Type 1 diabetes is a team of experts who can put it all together, test it, modify the treatment where necessary, perfect the dosing in a number of animal models and get the treatment into clinical trials as quickly as possible.
PharmaCyte's CEO, Kenneth L. Waggoner, has assembled 17 experts in the field of diabetes from all over the globe. This group makes up PharmaCyte's International Diabetes Consortium. They have all come together to work toward one goal -- developing an "artificial pancreas" or a "cure" for insulin dependent diabetes. All of these experts are working at the same time in their specific area of expertise rather than waiting for each experiment to run its course before moving on to the next group of experts. It is this approach that should expedite PharmaCyte's path to human clinical trials. PharmaCyte's approach should provide answers more quickly for those larger biopharmaceuticals that expect to win the race to the first truly long-term successful type 1 diabetes treatment.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
For more information: www.stockmarketmediagroup.com.
$PMCB PharmaCyte Biotech on Schedule for 2016 Cancer Clinical Trial in Pancreatic Cancer
SILVER SPRING, Md., Feb. 24, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, issued a further update on its upcoming clinical trial in pancreatic cancer. In this update, PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, clarifies statements made earlier this week that reportedly confused numerous shareholders and potential investors.
“Last Monday I tried to address certain issues that shareholders and potential investors have raised repeatedly about our upcoming clinical trial and provide an update on our efforts to complete the process of preparing the Investigational New Drug application (IND) that PharmaCyte must submit to the FDA to start our clinical trial in pancreatic cancer. Given the number of telephone calls and emails the Company has received since that update was published, it has become apparent that the update caused confusion and raised issues of concern that were never intended.
“When it was stated on Monday that the expected ‘start date’ for PharmaCyte’s clinical trial in pancreatic cancer remains difficult to announce with certainty, we were not implying that we aren’t still on schedule to get into the clinic in 2016 or that we don’t have any idea when we will be in the clinic. We plan to be in the clinic well before the end of this year. It was simply a statement that intended to refrain from announcing a specific date or time period for starting the trial because much of what is left to complete is out of our control.
“PharmaCyte is involved in a well-planned, detailed and methodical process to insure that every aspect of the IND is correct before we submit the IND to the FDA. As the “Sponsor” of the IND, it is our responsibility to insure that the Chemistry, Manufacturing and Controls (CMC) section of the IND is complete and accurate in every respect. We are working with Translational Drug Development (TD2), Chamow & Associates (Chamow) and Austrianova in completing everything that is required. It is a process that began last year and is well underway.
“TD2 is fully engaged and working diligently in all aspects of preparing for the clinical trial. With respect to developing the CMC information, the process is complicated, labor intensive and highly technical. But with TD2 taking the lead, working in concert with Chamow and Austrianova, I am very confident that our schedule is on track.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: info@PharmaCyte.com
$PMCB PharmaCyte Biotech on Schedule for 2016 Cancer Clinical Trial in Pancreatic Cancer
SILVER SPRING, Md., Feb. 24, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, issued a further update on its upcoming clinical trial in pancreatic cancer. In this update, PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, clarifies statements made earlier this week that reportedly confused numerous shareholders and potential investors.
“Last Monday I tried to address certain issues that shareholders and potential investors have raised repeatedly about our upcoming clinical trial and provide an update on our efforts to complete the process of preparing the Investigational New Drug application (IND) that PharmaCyte must submit to the FDA to start our clinical trial in pancreatic cancer. Given the number of telephone calls and emails the Company has received since that update was published, it has become apparent that the update caused confusion and raised issues of concern that were never intended.
“When it was stated on Monday that the expected ‘start date’ for PharmaCyte’s clinical trial in pancreatic cancer remains difficult to announce with certainty, we were not implying that we aren’t still on schedule to get into the clinic in 2016 or that we don’t have any idea when we will be in the clinic. We plan to be in the clinic well before the end of this year. It was simply a statement that intended to refrain from announcing a specific date or time period for starting the trial because much of what is left to complete is out of our control.
“PharmaCyte is involved in a well-planned, detailed and methodical process to insure that every aspect of the IND is correct before we submit the IND to the FDA. As the “Sponsor” of the IND, it is our responsibility to insure that the Chemistry, Manufacturing and Controls (CMC) section of the IND is complete and accurate in every respect. We are working with Translational Drug Development (TD2), Chamow & Associates (Chamow) and Austrianova in completing everything that is required. It is a process that began last year and is well underway.
“TD2 is fully engaged and working diligently in all aspects of preparing for the clinical trial. With respect to developing the CMC information, the process is complicated, labor intensive and highly technical. But with TD2 taking the lead, working in concert with Chamow and Austrianova, I am very confident that our schedule is on track.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: info@PharmaCyte.com
$PMCB All About PMCB
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119226438
$PMCB All About PMCB
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119226438
$PMCB PharmaCyte Biotech Addresses Development of Targeted Cannabinoid Chemotherapy
SILVER SPRING, Md., March 01, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Scientific Advisory Board member Mark L. Rabe, MD, was a featured speaker at a Physicians Roundtable that took place in San Diego this past weekend. The Physicians Roundtable was designed to educate local physicians and health care providers on the topic: “The Endocannabinoid System: Leveraging the Largest Receptor System in the Human Body.”
Dr. Rabe’s presentation, “The Evolution of Medical Cannabis,” traced the history of Cannabis from ancient times to the present day, citing numerous references from the proliferation of medical literature that document the anti-cancer, pain-relieving, anti-inflammatory and neuroprotective effects of the “phyto”-cannabinoid molecules contained in the Cannabis plant. Looking to the future, Dr. Rabe explained how PharmaCyte is seeking to leverage the body’s endocannabinoid system through development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with the versatile Cell-in-a-Box® live-cell encapsulation platform. This research is being conducted for PharmaCyte by researchers at the University of Northern Colorado (UNC) under a Schedule 1 license successfully obtained from the U.S. Drug Enforcement Agency.
"In order to provide better care to their patients, it is very heartening to see health care professionals dedicate precious time on a Saturday morning to become more educated in the recommendation of an herbal medicine that a significant – and growing – number of patients report works better, with far fewer side effects, than the pharmaceutical alternatives,” commented Dr. Rabe. “The work being conducted at UNC to utilize Cell-in-a-Box® live cell encapsulation in combination with a unique bioengineered cell line to activate cannabinoid prodrugs in a targeted fashion to treat cancer, and potentially other diseases, exemplifies where things are headed in the future.”
A copy of Dr. Rabe’s slide deck and references are posted at the PharmaCyte Biotech website: http://www.PharmaCyte.com/media
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
$PMCB PharmaCyte Biotech Addresses Development of Targeted Cannabinoid Chemotherapy
SILVER SPRING, Md., March 01, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Scientific Advisory Board member Mark L. Rabe, MD, was a featured speaker at a Physicians Roundtable that took place in San Diego this past weekend. The Physicians Roundtable was designed to educate local physicians and health care providers on the topic: “The Endocannabinoid System: Leveraging the Largest Receptor System in the Human Body.”
Dr. Rabe’s presentation, “The Evolution of Medical Cannabis,” traced the history of Cannabis from ancient times to the present day, citing numerous references from the proliferation of medical literature that document the anti-cancer, pain-relieving, anti-inflammatory and neuroprotective effects of the “phyto”-cannabinoid molecules contained in the Cannabis plant. Looking to the future, Dr. Rabe explained how PharmaCyte is seeking to leverage the body’s endocannabinoid system through development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with the versatile Cell-in-a-Box® live-cell encapsulation platform. This research is being conducted for PharmaCyte by researchers at the University of Northern Colorado (UNC) under a Schedule 1 license successfully obtained from the U.S. Drug Enforcement Agency.
"In order to provide better care to their patients, it is very heartening to see health care professionals dedicate precious time on a Saturday morning to become more educated in the recommendation of an herbal medicine that a significant – and growing – number of patients report works better, with far fewer side effects, than the pharmaceutical alternatives,” commented Dr. Rabe. “The work being conducted at UNC to utilize Cell-in-a-Box® live cell encapsulation in combination with a unique bioengineered cell line to activate cannabinoid prodrugs in a targeted fashion to treat cancer, and potentially other diseases, exemplifies where things are headed in the future.”
A copy of Dr. Rabe’s slide deck and references are posted at the PharmaCyte Biotech website: http://www.PharmaCyte.com/media
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed. PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, a chemotherapy drug which needs to be activated in the body (ifosfamide) is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When the ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the chemotherapy drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com
$PMCB Uptick Network – Interview with CEO Ken Waggoner with PharmaCyte Biotech, Inc.
Everett Jolly interviews Ken Waggoner, CEO of PharmaCyte Biotech, Inc. (PMCB) and talks about developing a new therapy for people with cancer and diabetes called ‘Cell In a Box’.
We are pleased to share the following UPTICK Network Stock Day Radio Show and Podcast content. The CEOs interviewed on Stock Day did not incur any charges for their time with Uptick CEO Everett Jolly. Uptick staff is always looking for exciting companies to bring to our interested readers and listeners. Contact us if you would like further information on the UPTICK Network or Uptick services.
https://upticknewswire.com/?powerpress_pinw=36793-podcast
$PMCB Uptick Network – Interview with CEO Ken Waggoner with PharmaCyte Biotech, Inc.
Everett Jolly interviews Ken Waggoner, CEO of PharmaCyte Biotech, Inc. (PMCB) and talks about developing a new therapy for people with cancer and diabetes called ‘Cell In a Box’.
We are pleased to share the following UPTICK Network Stock Day Radio Show and Podcast content. The CEOs interviewed on Stock Day did not incur any charges for their time with Uptick CEO Everett Jolly. Uptick staff is always looking for exciting companies to bring to our interested readers and listeners. Contact us if you would like further information on the UPTICK Network or Uptick services.
https://upticknewswire.com/?powerpress_pinw=36793-podcast
$PMCB Valuing PharmaCyte Biotech's New Treatment Option for Pancreatic Cancer
BALTIMORE, MD / ACCESSWIRE / March 9, 2016 / The current gold standard of care for patients with advanced, inoperable pancreatic cancer is the combination therapy of Abraxane® + gemcitabine, which was approved by the U.S. Food and Drug Administration (FDA) in late 2013. Another treatment, which is not used as widely, is FOLFIRINOX, a four-drug combination therapy. These treatments offer varying degrees of efficacy but what happens to the patients when they no longer respond to these therapies? With limited options currently available, PharmaCyte Biotech (PMCB) is set to launch a new, mid-stage clinical trial in 2016 to specifically address what is clearly an unmet medical need and potentially increase the lifespan prospects for these late stage pancreatic cancer sufferers.
Positive results from this landmark trial would move PharmaCyte toward the front of the pack of cancer treatment providers, substantially enhance the value of the Company and attract the attention of major pharmaceutical companies. After all, a successful trial could be the trigger to change the way advanced inoperable pancreatic cancer is treated. It would finally give patients, who no longer respond to the premier combination therapy, a viable option. PharmaCyte's pancreatic cancer treatment (Cell-in-a-Box®+ low-dose ifosfamide chemotherapy) seeks to satisfy this critical unmet medical need by acting as a consolidation (and post- Abraxane® + gemcitabine or FOLFIRINOX) therapy.
Huge Addressable Market
A recent report issued by Research and Markets suggests that the size of the pancreatic cancer therapeutic markets in just the major developed countries will approach $3 billion in the next 5 years. However, the near term addressable market for PharmaCyte's therapy in the U.S. alone is substantial. A typical current price tag for pancreatic cancer therapy for the roughly 43,000 patients diagnosed with the disease each year ranges anywhere from $50,000 - $75,000. More than 60% of this patient group, or roughly 25,000 patients, will no longer respond to the premier combination therapy (Abraxane® + gemcitabine or FOLFIRINOX) and require a new, or consolidation therapy. Therefore, should PharmaCyte ultimately receive FDA approval for its treatment, the Company's initial target market size would range from $1.25 billion to $1.8 billion, depending upon pricing for the Company's therapy. Clearly, there is tremendous underlying value in PharmaCyte and its novel therapy.
The Trial
PharmaCyte has designed a Phase 2b clinical trial that will include a hard-stop at 6 months to evaluate the data. The primary endpoints of the trial will essentially mirror some of the primary endpoints of other treatments that have received FDA approval, such as Abraxane®. These include progression-free survival (PFS) and the side effects experienced from the combination treatment that occurs in the patients. PFS is the time that elapses from the first day of treatment until the disease gets worse and will be measured and determined at 6 and 12 months. The occurrence of any side effects will be monitored throughout the trial.
The trial design also includes a series of measurable secondary endpoints. These include:
- Onset of pain and need for pain medications
- Whether inoperable tumors become operable as a result of treatment;
- Change in tumor size; and
- Patient overall quality of life during the treatment.
The Company's consolidation therapy approach is poised to emerge as a win-win for the Company and patients alike. This positioning, along with an innovative trial design, enable PharmaCyte to launch and complete this clinical trial at a substantially reduced cost and shorter time period relative to typical studies since it will be conducted with fewer patients and in key sites in the U.S. and abroad. In addition, by measuring pain as one of the secondary endpoints, the Company eliminates the need to launch costly separate trials or studies to track the unbearable and untreatable pain that is associated with pancreatic cancer in 20-25% of patients. Finally, because the design of the trial allows for the release of interim data relatively quickly, it only enhances the value of the therapy to the Company and prospective patients.
Impact of Potential Approval
Positioning its innovative treatment as the next or last stage therapy for the difficult patient treatment group may be the fastest route to PharmaCyte's FDA approval, as there is no truly effective therapy for patients at this stage that can materially extend survival rates and improve their quality of life. Measurements will also be taken to determine if PharmaCyte's treatment can convert an inoperable tumor to an operable one. If tumor shrinkage data proves encouraging, it could have a materially favorable impact on a trial's outcome, let alone the quality of life and lifespan of pancreatic cancer patients, and the overall valuation of the Company among cancer treatment leaders.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release reflects our most recently published sponsored research article on PharmaCyte Biotech, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. In 2015, Goldman Small Cap Research was compensated by a third party (not PharmaCyte or anyone affiliated with PharmaCyte) in the amount of $22,000 for investment research services that includes the publication of research reports, updates, and a series of articles.
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com
SOURCE: Goldman Small Cap Research
$PMCB Valuing PharmaCyte Biotech's New Treatment Option for Pancreatic Cancer
BALTIMORE, MD / ACCESSWIRE / March 9, 2016 / The current gold standard of care for patients with advanced, inoperable pancreatic cancer is the combination therapy of Abraxane® + gemcitabine, which was approved by the U.S. Food and Drug Administration (FDA) in late 2013. Another treatment, which is not used as widely, is FOLFIRINOX, a four-drug combination therapy. These treatments offer varying degrees of efficacy but what happens to the patients when they no longer respond to these therapies? With limited options currently available, PharmaCyte Biotech (PMCB) is set to launch a new, mid-stage clinical trial in 2016 to specifically address what is clearly an unmet medical need and potentially increase the lifespan prospects for these late stage pancreatic cancer sufferers.
Positive results from this landmark trial would move PharmaCyte toward the front of the pack of cancer treatment providers, substantially enhance the value of the Company and attract the attention of major pharmaceutical companies. After all, a successful trial could be the trigger to change the way advanced inoperable pancreatic cancer is treated. It would finally give patients, who no longer respond to the premier combination therapy, a viable option. PharmaCyte's pancreatic cancer treatment (Cell-in-a-Box®+ low-dose ifosfamide chemotherapy) seeks to satisfy this critical unmet medical need by acting as a consolidation (and post- Abraxane® + gemcitabine or FOLFIRINOX) therapy.
Huge Addressable Market
A recent report issued by Research and Markets suggests that the size of the pancreatic cancer therapeutic markets in just the major developed countries will approach $3 billion in the next 5 years. However, the near term addressable market for PharmaCyte's therapy in the U.S. alone is substantial. A typical current price tag for pancreatic cancer therapy for the roughly 43,000 patients diagnosed with the disease each year ranges anywhere from $50,000 - $75,000. More than 60% of this patient group, or roughly 25,000 patients, will no longer respond to the premier combination therapy (Abraxane® + gemcitabine or FOLFIRINOX) and require a new, or consolidation therapy. Therefore, should PharmaCyte ultimately receive FDA approval for its treatment, the Company's initial target market size would range from $1.25 billion to $1.8 billion, depending upon pricing for the Company's therapy. Clearly, there is tremendous underlying value in PharmaCyte and its novel therapy.
The Trial
PharmaCyte has designed a Phase 2b clinical trial that will include a hard-stop at 6 months to evaluate the data. The primary endpoints of the trial will essentially mirror some of the primary endpoints of other treatments that have received FDA approval, such as Abraxane®. These include progression-free survival (PFS) and the side effects experienced from the combination treatment that occurs in the patients. PFS is the time that elapses from the first day of treatment until the disease gets worse and will be measured and determined at 6 and 12 months. The occurrence of any side effects will be monitored throughout the trial.
The trial design also includes a series of measurable secondary endpoints. These include:
- Onset of pain and need for pain medications
- Whether inoperable tumors become operable as a result of treatment;
- Change in tumor size; and
- Patient overall quality of life during the treatment.
The Company's consolidation therapy approach is poised to emerge as a win-win for the Company and patients alike. This positioning, along with an innovative trial design, enable PharmaCyte to launch and complete this clinical trial at a substantially reduced cost and shorter time period relative to typical studies since it will be conducted with fewer patients and in key sites in the U.S. and abroad. In addition, by measuring pain as one of the secondary endpoints, the Company eliminates the need to launch costly separate trials or studies to track the unbearable and untreatable pain that is associated with pancreatic cancer in 20-25% of patients. Finally, because the design of the trial allows for the release of interim data relatively quickly, it only enhances the value of the therapy to the Company and prospective patients.
Impact of Potential Approval
Positioning its innovative treatment as the next or last stage therapy for the difficult patient treatment group may be the fastest route to PharmaCyte's FDA approval, as there is no truly effective therapy for patients at this stage that can materially extend survival rates and improve their quality of life. Measurements will also be taken to determine if PharmaCyte's treatment can convert an inoperable tumor to an operable one. If tumor shrinkage data proves encouraging, it could have a materially favorable impact on a trial's outcome, let alone the quality of life and lifespan of pancreatic cancer patients, and the overall valuation of the Company among cancer treatment leaders.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release reflects our most recently published sponsored research article on PharmaCyte Biotech, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. In 2015, Goldman Small Cap Research was compensated by a third party (not PharmaCyte or anyone affiliated with PharmaCyte) in the amount of $22,000 for investment research services that includes the publication of research reports, updates, and a series of articles.
Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com
SOURCE: Goldman Small Cap Research
$PMCB All Videos About PMCB
$PMCB PharmaCyte Biotech - Diabetes Treatment Program
$PMCB All Videos About PMCB
$PMCB PharmaCyte Biotech - Diabetes Treatment Program
$PMCB The Evolution of Medical Cannabis Mark L. Rabe, MD
http://pharmacyte.com/wp-content/uploads/2016/02/Rabe_CW_Evolution_of-Medical_Cannabis_2016_02_27_vFINAL.pdf
$PMCB The Evolution of Medical Cannabis Mark L. Rabe, MD
http://pharmacyte.com/wp-content/uploads/2016/02/Rabe_CW_Evolution_of-Medical_Cannabis_2016_02_27_vFINAL.pdf